Collaborative Networks Driving Regulatory Transformation in Latin America
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
Established over 35 years ago, CHEMO operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, both for human and animal health.
While the main offices are located in Madrid, Lugano and Buenos Aires, CHEMO is acting worldwide, creating a broad and balanced manufacturing and commercial network across major pharmaceutical markets in Europe, America, Asia and Africa, to address global opportunities and customers` needs.
CHEMO`s activity is organized in three synergistic business areas: Industrial, Branded and Biotech, with over 5,000 professionals in more than 40 countries, across 4 continents, 10 state-of-the-art manufacturing facilities, 9 specialized R&D centers, 12 commercial offices and 33 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world.
CHEMO believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to safe, quality and affordable medicines, and to continuously expand our efforts and R&D investment to develop new and better therapies.
Chemo Argentina
Edificio INSUD Paraguay 1535
C1061 ABC Buenos Aires , Argentina.
Tel: + 54 11 4872 11 00
Fax: + 54 11 4872 12 01
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s…
A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4…
An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
Axios International has been designing and implementing access to healthcare solutions in collaboration with the pharmaceutical industry and other healthcare players across Latin America (LatAm), Europe, the Middle East, Africa,…
Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth…
See our Cookie Privacy Policy Here
